利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.023 秒)

    Method of preparing N,N,N-trimethylsphingosine
    5.
    发明授权
    Method of preparing N,N,N-trimethylsphingosine 失效
    制备N，N，N-三甲基鞘氨醇的方法

    公开(公告)号：US5248824A

    公开(公告)日：1993-09-28

    申请号：US879332

    申请日：1992-05-07

    申请人： Yasuyuki Igarashi ,  Mahammad N. Ahmad ,  Hirofumi Okoshi ,  Sen-Itiroh Hakomori

    发明人： Yasuyuki Igarashi ,  Mahammad N. Ahmad ,  Hirofumi Okoshi ,  Sen-Itiroh Hakomori

    IPC分类号： C07C215/40

    CPC分类号： C07C215/40

    摘要： The invention relates to a novel compound, compositions and medicaments thereof and a method of inhibiting cell proliferation, platelet aggregation (induced by various factors), and inhibiting malignant phenotypes of tumor cells such as those having a metastatic property, using said compound, composition or medicament. N,N,N-trimethylsphingosine shows superior cell proliferation inhibitory and anti-metastatic activity over related compounds.

    摘要翻译： 本发明涉及一种新型化合物，其组合物及其药物，以及抑制细胞增殖，血小板聚集（各种因素诱导），抑制肿瘤细胞恶性表型的方法，使用所述化合物，组合物或 药物。 N，N，N-三甲基鞘氨醇对相关化合物显示出优异的细胞增殖抑制和抗转移活性。

    Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with carbohydrate-carrier conjugates
    10.
    发明授权
    Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with carbohydrate-carrier conjugates 失效
    通过用碳水化合物 - 载体缀合物免疫，针对人类癌症相关抗原的单克隆抗体和疫苗开发

    公开(公告)号：US5660834A

    公开(公告)日：1997-08-26

    申请号：US400480

    申请日：1995-03-08

    申请人： Thomas J. Kjeldsen ,  Henrik Clausen ,  Anil Singhal ,  Tatsushi Toyokuni ,  Helio K. Takahashi ,  Sen-Itiroh Hakomori

    发明人： Thomas J. Kjeldsen ,  Henrik Clausen ,  Anil Singhal ,  Tatsushi Toyokuni ,  Helio K. Takahashi ,  Sen-Itiroh Hakomori

    IPC分类号： A61K39/00 ,  C07K14/47 ,  C07K16/30 ,  A61K38/14 ,  A61K39/39 ,  C07K14/82

    CPC分类号： C07K14/4727 ,  A61K39/0011 ,  C07K16/30 ,  A61K2039/55572 ,  A61K2039/6018 ,  A61K2039/6081 ,  A61K2039/645

    摘要： A vaccine and method to prevent growth and replication of cancer cells that express a core structure of a mucin-type glycoprotein is disclosed. The vaccine comprises: (a) a pharmaceutically effective amount of an antigen comprising a purified mucin-type glycoprotein or a chemically synthesized mucin-type glycoprotein carbohydrate determinant conjugated to a carrier peptide or macromolecule, wherein said mucin-type glycoprotein expresses or carries the core structure of a mucin-type glycoprotein expressed on said cancer cells; and (b) a pharmaceutically acceptable carrier including natural or synthetic adjuvants. The method comprises administering the above-described vaccine to a host. A medicament and method for treating cancer wherein the cancer cells express a core structure of a mucin-type glycoprotein is disclosed. The medicament comprises: (a) a pharmaceutically effective amount of an anti-cancer antibody or fragment comprising a binding site thereof, said anti-cancer antibody having been produced against a purified core structure of a mucin-type glycoprotein; and (b) a pharmaceutically acceptable carrier, diluent or excipient. The method comprises administering the above-described medicament to a host.

    摘要翻译： 公开了一种用于预防表达粘蛋白型糖蛋白的核心结构的癌细胞的生长和复制的疫苗和方法。 疫苗包含：（a）药学有效量的抗原，其包含与载体肽或大分子缀合的纯化的粘蛋白型糖蛋白或化学合成的粘蛋白型糖蛋白碳水化合物决定簇，其中所述粘蛋白型糖蛋白表达或携带核心 在所述癌细胞上表达的粘蛋白型糖蛋白的结构; 和（b）包括天然或合成佐剂的药学上可接受的载体。 该方法包括将上述疫苗给予宿主。 公开了一种治疗癌症的药物和方法，其中癌细胞表达粘蛋白型糖蛋白的核心结构。 药物包括：（a）药学有效量的抗癌抗体或包含其结合位点的片段，所述抗癌抗体是针对粘蛋白型糖蛋白的纯化核心结构产生的; 和（b）药学上可接受的载体，稀释剂或赋形剂。 该方法包括将上述药物施用于宿主。